R Zhao1, Y Jiang2. 1. Department of Ultrasonic, ChongQing Traditional Chinese Medicine Hospital, No. 6, Panxi 7 branch Road, Jiangbei District, 400021, Chongqing, China. 2. Department of Ultrasonic, ChongQing Traditional Chinese Medicine Hospital, No. 6, Panxi 7 branch Road, Jiangbei District, 400021, Chongqing, China. 191390247@qq.com.
Abstract
BACKGROUND: Riociguat treatment might be beneficial for pulmonary arterial hypertension. However, the results of studies to date are controversial. We conducted a systematic review and meta-analysis to explore the influence of riociguat treatment on pulmonary arterial hypertension. METHODS: The PubMed, Embase, Web of science, EBSCO, and Cochrane Library databases were systematically searched. Randomized controlled trials (RCTs) assessing the effect of riociguat treatment on pulmonary arterial hypertension were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. This meta-analysis was performed using the random effects model. RESULTS: Seven RCTs were included in the meta-analysis. Compared with a control intervention in pulmonary arterial hypertension, riociguat treatment was able to substantially improve results of the six-minute walking distance (6-MWD; standardized mean difference [SMD] = 0.53; 95% CI = 0.36-0.69; p < 0.00001), EQ-5D score (SMD = 0.35; 95% CI = 0.15-0.54; p = 0.0005), and cardiac index (SMD = 0.94; 95% CI = 0.59-1.29; p < 0.00001). The Living With Pulmonary Hypertension (LPH) score (SMD = -0.33; 95% CI = -0.50--0.17; p < 0.0001) and pulmonary vascular resistance (PVR; SMD = -0.88; 95% CI = -1.05--0.70; p < 0.00001) were significantly reduced after riociguat treatment. There was no increase in adverse events with riociguat treatment compared with the control intervention (RR = 1.04; 95% CI = 0.98-1.09; p = 0.19). CONCLUSION: Riociguat treatment for pulmonary arterial hypertension led to a significant increase in the 6‑MWD, EQ-5D score, and cardiac index, as well as a decrease in LPH score and PVR.
BACKGROUND:Riociguat treatment might be beneficial for pulmonary arterial hypertension. However, the results of studies to date are controversial. We conducted a systematic review and meta-analysis to explore the influence of riociguat treatment on pulmonary arterial hypertension. METHODS: The PubMed, Embase, Web of science, EBSCO, and Cochrane Library databases were systematically searched. Randomized controlled trials (RCTs) assessing the effect of riociguat treatment on pulmonary arterial hypertension were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. This meta-analysis was performed using the random effects model. RESULTS: Seven RCTs were included in the meta-analysis. Compared with a control intervention in pulmonary arterial hypertension, riociguat treatment was able to substantially improve results of the six-minute walking distance (6-MWD; standardized mean difference [SMD] = 0.53; 95% CI = 0.36-0.69; p < 0.00001), EQ-5D score (SMD = 0.35; 95% CI = 0.15-0.54; p = 0.0005), and cardiac index (SMD = 0.94; 95% CI = 0.59-1.29; p < 0.00001). The Living With Pulmonary Hypertension (LPH) score (SMD = -0.33; 95% CI = -0.50--0.17; p < 0.0001) and pulmonary vascular resistance (PVR; SMD = -0.88; 95% CI = -1.05--0.70; p < 0.00001) were significantly reduced after riociguat treatment. There was no increase in adverse events with riociguat treatment compared with the control intervention (RR = 1.04; 95% CI = 0.98-1.09; p = 0.19). CONCLUSION:Riociguat treatment for pulmonary arterial hypertension led to a significant increase in the 6‑MWD, EQ-5D score, and cardiac index, as well as a decrease in LPH score and PVR.
Authors: Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marius M Hoeper; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Lewis J Rubin; Arno Fritsch; Neil Davie; Hossein-Ardeschir Ghofrani Journal: J Heart Lung Transplant Date: 2016-12-24 Impact factor: 10.247
Authors: Charles Khouri; Marion Lepelley; Matthieu Roustit; François Montastruc; Marc Humbert; Jean-Luc Cracowski Journal: Chest Date: 2017-12-21 Impact factor: 9.410
Authors: Hossein-Ardeschir Ghofrani; Andrea M D'Armini; Friedrich Grimminger; Marius M Hoeper; Pavel Jansa; Nick H Kim; Eckhard Mayer; Gerald Simonneau; Martin R Wilkins; Arno Fritsch; Dieter Neuser; Gerrit Weimann; Chen Wang Journal: N Engl J Med Date: 2013-07-25 Impact factor: 91.245
Authors: Markus Follmann; Nils Griebenow; Michael G Hahn; Ingo Hartung; Franz-Josef Mais; Joachim Mittendorf; Martina Schäfer; Hartmut Schirok; Johannes-Peter Stasch; Friederike Stoll; Alexander Straub Journal: Angew Chem Int Ed Engl Date: 2013-08-20 Impact factor: 15.336
Authors: Nick H Kim; Andrea M D'Armini; Friedrich Grimminger; Ekkehard Grünig; Marius M Hoeper; Pavel Jansa; Eckhard Mayer; Claus Neurohr; Gérald Simonneau; Adam Torbicki; Chen Wang; Arno Fritsch; Neil Davie; Hossein-Ardeschir Ghofrani Journal: Heart Date: 2016-12-23 Impact factor: 5.994
Authors: R Condliffe; D G Kiely; J S R Gibbs; P A Corris; A J Peacock; D P Jenkins; K Goldsmith; J G Coghlan; J Pepke-Zaba Journal: Eur Respir J Date: 2008-10-01 Impact factor: 16.671